Use of naltrexone as a provocative test for hypothalamic-pituitary hormone function |
| |
| Authors: | J H Mendelson N K Mello P Cristofaro A Skupny J Ellingboe |
| |
| Affiliation: | 1. Research Centre for the Neurosciences of Ageing, Academic Unit of Psychiatry and Addiction Medicine, School of Clinical Medicine, Medical School, Australian National University, Canberra, Australia;2. Graduate School of Medicine, University of Wollongong, Wollongong, Australia;3. School of Medicine, The University of Notre Dame, Fremantle, Australia;4. Clinical Research Centre, North Metropolitan Health Service – Mental Health, Perth, Australia;5. Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Australia;6. Florey Institute of Neurosciences and Mental Health, University of Melbourne, Melbourne, Australia;7. Memory Clinic, Skåne University Hospital, Malmö, Sweden;8. Department of Clinical Sciences, Lund University, Malmö, Sweden;9. Centre for Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden;10. Diagnostic Radiology, Department of Clinical Sciences, Lund University, Lund, Sweden;11. College of Engineering and Computer Science, The Australian National University, Canberra, Australia;1. Department of Psychiatry, University of Geneva, Switzerland;2. Service of Adult Psychiatry, Department of Mental Health and Psychiatry, University Hospitals of Geneva, Switzerland;3. Laboratory for Behavioral Neurology and Imaging of Cognition, Geneva Neuroscience Center, University of Geneva, Switzerland;4. Functional Neurology Research Group, Departments of Neurology and Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;5. Inpatient Psychiatry Division, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;6. Centre for Clinical Brain Sciences, Western General Hospital, NHS Lothian and University of Edinburgh, Edinburgh, UK;7. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA |
| |
| Abstract: | Naltrexone (50 mg) administration to normal adult women during the early follicular phase of the menstrual cycle (day 1 to day 4 following onset of menstruation) induced a significant elevation in plasma LH, prolactin, ACTH and cortisol levels. Orally administered naltrexone appears to be a safe and effective compound for assessing function of the hypothalamic-anterior pituitary axis in women. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
